Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

Inclusion Criteria

• •1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
• •2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
• •3. CD4+ lymphocyte cell count ≥ 300 cells/mm3 and no documented count \< or = 250 cells/mm3
• •4. Has not taken any antiretroviral therapy (ART) w/in 12 wks of Early Screening Visit
• •5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit
• •6. Clinically normal or "not clinically significant (NCS)" resting electrocardiogram
• •7. Women of reproductive potential must have a negative serum pregnancy test at Late Screening Visit \& a negative urine pregnancy test w/in 72 hrs prior to first dose of study medication, \& be non-lactating. Male \& female subjects must agree not to participate in a conception process from Early Screening Visit through Day 59.